SMAD3 and glomerulosclerosis: The PPARγ agonist rosiglitazone has been shown to inhibit mesangial cell proliferation, serine protease activity, and TGFβ expression, while activating the TGFβ-Smad3 signaling pathway, thereby preventing the progression of glomerular sclerosis [41].